Abstract
Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.
Introduction
In stark contrast to our growing understanding of mental illnesses, diagnoses and treatments heavily rely on the clinical interview rather than direct, reliable assays of brain function. The results are hardly surprising: we have not meaningfully improved clinically relevant endpoints for many serious mental illnesses in the last several decades (1). Recent advances in biomarker development, however, hold promise for ushering in a new era of precision medicine-style trials for treating psychiatric illnesses.
Biomarker-informed clinical trial approaches are becoming common in other fields of medicine [(2); for reviews see (3), (4)]. As one example, anti-neoplastic agents are currently selected not only based on what type of cancer a patient has and its stage, but also on the molecular phenotype and genetic aberrations unique to the cancer. Such biomarker-informed approaches are best exemplified by two conceptually related clinical trial designs: “basket” and “umbrella” trials (5, 6). Basket trials assess the effectiveness of a candidate drug based on the mechanism rather than the underlying cancer type. For example, a neoplastic drug which targets a specific genetic mutation would be given to cohorts, or “baskets,” of patients with cancers of different origin (i.e., prostate, breast, lung, etc.) who share molecular signatures, vastly expanding the number of patients that could benefit from such a precision intervention (7). Umbrella trials take patients with the same type of cancer, and assign them to treatment arms based on unique mutations—thus, every single arm is one spoke of the large “umbrella” of therapeutic interventions. As the prototypical example, the National Cancer Institute's MATCH trial recruits patients with advanced solid tumors, lymphomas and myelomas, performs extensive genotyping and molecular stratification, and places participants into one of over a dozen different treatment arms (8).
While psychiatry currently has no candidate biomarkers which have graduated from academic laboratories to guide treatments in real-world settings, the stage is being set for a future which successfully leverages a precision psychiatry approach. In this brief review, we provide an overview of what a precision psychiatry approach could look like using a well-validated translational electroencephalography (EEG) measure called mismatch negativity (MMN) as a candidate biomarker, and neurocognitive impairment in schizophrenia as a target disease dimension.
Schizophrenia and neurocognitive impairment
Schizophrenia (SZ) is characterized by positive (e.g., hallucinations, delusions, etc.) and negative (e.g., avolition, diminished emotional expressivity etc.) symptoms which contribute to functional impairment. Beyond these defining symptoms of SZ, hundreds of studies have suggested that neurocognitive impairments are both core features of the illness and robust determinants of psychosocial disability (9–12). Neurocognitive deficits in SZ are broad, and include abnormalities in perceptual functioning, attention, verbal and non-verbal memory, language, and executive functioning (13). The severity of deficits on these neuropsychological domains are directly linked to diminished community functioning and impaired activities of daily living (14, 15).
Indeed, recent analyses of over 1,400 patients with chronic psychoses recruited for the multi-site Consortium on the Genetics of Schizophrenia (COGS) provided strong empirical support for a hierarchical model linking cognition with functional outcome in SZ (16). In this study, structural equation modeling was used to better understand how functional outcome in SZ could be better understood in relation to symptoms, cognition and early auditory information processing (EAIP). Interestingly, abnormalities in EAIP, as indexed by EEG biomarkers, had a direct and causal effect on cognition, which in turn directly affected negative symptoms, impacting overall functional outcome. Particularly noteworthy was the finding that abnormalities in EEG biomarkers linked to EAIP also independently affected functional outcome in SZ patients.
Neurophysiological indicators have indexed abnormalities in EAIP in SZ for several decades, and differences in EAIP in patients are prominently featured as endophenotypes in genomic studies. The above analyses confirmed that the neurocognitive impairments in SZ appear to be a core disease component, reliably able to be measured and directly-linked to the symptoms and functional outcomes. Despite this advance, decades of clinical trials testing the effectiveness of currently approved antipsychotic medications and other novel therapeutics as putative pro-cognitive agents have failed to improve cognitive symptoms in SZ in any durable, meaningful way (17, 18). The development of novel pro-cognitive treatment strategies is therefore of paramount importance but remains a critical unmet need (19). These elements provide the ground on which biomarkers can be used to guide research and clinical implementation of novel precision-medicine therapeutic strategies in SZ.
Mismatch negativity: a neurophysiological biomarker for early auditory information processing
The usefulness of EEG measures in guiding new treatments depends on their ability to serve as biomarkers. Useful biomarkers must be accessible and measurable in preclinical models of disease; should be sufficiently well-characterized such that those biomarkers are linked to relevant underlying neural circuits and known mechanisms of dysfunction in psychiatric disease; and are able to be assessed in both healthy subjects and affected individuals. For usefulness in human trials biomarkers must be insensitive to practice or order effects, reliable, and responsive to interventions. To succeed in real-world settings, biomarker acquisition should also be scalable, low-cost, and suitable for use in multi-center studies.
All of the above criteria have been identified for biomarker development for neurocognitive impairment in SZ by a variety of expert consensus panels (20–23). The first panel, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, agreed that there was a lack of consensus on a well-accepted instrument for measuring neurocognition in clinical trials (20), on the best molecular targets for drug development, on the optimal trial design for studies of those targets, and how regulatory agencies ought to approve and label novel agents. The outcome of this initiative identified the following criteria as desirable in an FDA-approved battery for use in clinical outcome measures: high test-retest reliability, utility as a repeated measure, relationship to functional outcome, tolerability and practicality, and responsivity to pro-cognitive therapeutics. The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, launched after MATRICS, further expanded on the MATRICS criteria by adding that measures should have construct validity, be mechanistically related to relevant neural circuitry, and be measurable in animal models (21, 22).
At the time of CNTRICS, mismatch negativity (MMN) was already considered a mature neurophysiologic biomarker based on meeting the above criteria, and generally believed to be ready for widespread implementation in clinical trial studies (21, 23). In fact, as a real-world readiness demonstration, MMN has been extensively characterized in multi-center trials without the use of highly-trained specialists or centers (16, 24).
MMN is an event-related potential and a neurophysiological measure of EAIP that is evoked when a train of “standard” auditory stimuli is interrupted by an oddball or “deviant” stimulus that differs from standards as shown in Figure 1 (25–27). Differences from standard stimuli in pitch, duration, intensity, or spatial location can elicit a deviant MMN response. MMN is pre-attentive, primarily reflects an automatic response to sensory stimuli, and is able to be evoked without effort, behavioral response, or conscious awareness (26–31). After auditory deviant stimuli presentation, MMN onset begins after ~50 ms and peaks after an additional 100–150 ms (32, 33). Localization studies have consistently revealed cortical sources located in broadly distributed temporal, frontal, and parietal brain regions (34–36).
Figure 1
Mismatch negativity. The left graph represents the event related potentials evoked by trains of standard stimuli (S; in red) with interposed rare deviant stimuli (blue) in both healthy subject (solid lines) and patients with schizophrenia (dashed lines). The right graph represents the difference waveform, a negative inflection 100–200 ms after stimulus onset which is called mismatch negativity (MMN). Patients with schizophrenia show a reduction in the amplitude of MMN when compared to healthy subjects.
Reduction of auditory MMN amplitude was reported over two decades ago in SZ and has been replicated numerous times (37). MMN deficits are found in those with chronic psychosis (27, 37–50), in unmedicated SZ patients (29, 40, 46, 47, 51, 52), and are shown to be resistant to antipsychotics (46, 53–58). Abnormal MMN is also found in recent-onset psychosis as well as prodromal illness (30, 51, 59–66). Baseline MMN amplitude appears to be smaller in clinically high risk populations who eventually develop psychosis at follow up, and MMN in those who do not convert appears to be similar to age-matched controls (30, 51, 63). Strikingly, MMN amplitude seems to anticipate time-to-convert to psychosis—more severe MMN deficits relate to shorter time for psychosis to declare (51, 63).
Mechanistically, auditory MMN is thought to be an index of N-methyl-D-aspartate receptor (NMDA) functioning (67, 68). NMDA receptor antagonists diminish MMN in non-human primates, and ketamine, an NMDA antagonist, reduces MMN in healthy control human subjects (69–75). Lower baseline MMN is also associated with psychotic-like behavioral effects experienced by healthy subjects when exposed to ketamine (72). Furthermore, MMN has shown to be highly heritable with amplitude reductions present in asymptomatic first-degree relatives of those with SZ (76–80). MMN deficits are also found in patients with chromosome 22q deletion, which result in congenital syndromes associated with SZ-like psychoses (81).
Arguably, the most important metric of biomarker applicability in psychiatric illnesses is the ability to track functional outcome. In patients with SZ, several studies have detailed that MMN deficits are able to account for a large degree of variance in cognitive and psychosocial functioning, as well as the ability to achieve or maintain independent living (17, 34, 46, 64, 82–86).
Biomarker-informed insights for a precision medicine approach: MMN and cognitive enhancement strategies in schizophrenia
Given the cognitive deficits observed in SZ, many studies have attempted to use pro-cognitive drugs to help attenuate this dimension of illness (87). In particular, there has been great interest in the NMDA receptor antagonist, memantine, which has been approved for use in Alzheimer's disease (88, 89).
Memantine is a non-competitive moderate affinity NMDAR antagonist (90, 91). It is thought to bind the same site as magnesium, an endogenous blocker of the NMDA receptor channel, and impedes current flow only if the NMDA receptor channel is open. Upon depolarization, memantine rapidly leaves the NMDA receptor channel. Thus, functionally, memantine is thought to block sustained and pathological activation of NMDA receptors, but not affect physiological activity. In this sense, memantine is unique from other NMDA receptor antagonists which have slower un-blocking kinetics, (i.e., ketamine, phencyclidine). Interestingly, ketamine and phencyclidine are well-known to produce psychotogenic effects but memantine does not exacerbate psychosis or cognitive deficits in antipsychotic medicated patients (92–96). This discrepancy remains an area of active investigation.
In clinical trials with Alzheimer's disease patients, memantine has been found to have a modest pro-cognitive impact (97, 98). However, clinical trials using memantine in SZ targeting cognitive impairment have been inconsistent. Meta-analyses have suggested that memantine is associated with improvement in cognitive tests such as the Mini-Mental State Exam (94). While some double blind randomized clinical trials where memantine has been added on to antipsychotic medications also report reduction in cognitive deficits, others have not, including a study which showed cognitive improvement reported at 12 weeks was lost at 52 weeks (99–101). Given these discrepancies, it has been speculated that patient factors may be obscuring signals of memantine effects on cognition in SZ. Indeed, there is evidence that suggests that within the spectrum of illnesses in chronic psychotic disorders like SZ there exist separable cognitive “biotypes” which have different profiles of cognitive impairment (102, 103). Thus, without a clearer understanding of knowing which patients with SZ are able to experience benefits of memantine, results from clinical trials using such a pro-cognitive intervention—and more broadly, all pro-cognitive interventions in SZ—are difficult to interpret.
However, recent work assessing the effect of memantine on MMN could provide insights into a precision-medicine approach (94, 96, 103, 104). For example, our group has used a double blind single-dose placebo-controlled trial assessing the effects of memantine on MMN in patients with SZ (95, 96). This study employed a within-subject cross-over design such that all participants were randomized to receive either placebo or memantine, and 7 days later, receive the other intervention, thus allowing for each subject to serve as his or her own baseline. MMN was assessed ~ 6 h after placebo or memantine ingestion, which is the approximate Tmax of memantine, on both testing days. We found that memantine enhanced MMN in patients with SZ; since improved MMN is associated with less cognitive impairment and greater psychosocial success, this type of signal suggests that MMN could be a biomarker of treatment engagement in pro-cognitive interventions. While only a single dose of memantine would not be expected to durably improve cognition, the ability of memantine to alter MMN in a patient could signify that such an individual has the neural plasticity to benefit from pro-cognitive interventions (96, 103, 105). Indeed, not all patients in the cohort showed MMN enhancement—but, these results suggest that for future trials which aim to test the effectiveness of pro-cognitive medications, MMN malleability in response to early exposure to a putative pharmacologic agent could be important for enriching trials to maximize a therapeutic signal.
Beyond medication interventions, MMN also has the potential to predict gains in non-pharmacologic pro-cognitive interventions in SZ. For example, there has been significant interest in using targeted cognitive training (TCT) for enhancing cognition in patients with chronic psychoses (106, 107). TCT is an emerging computerized, auditory-based intervention which aims to improve EAIP through adaptive exercises with participants (105, 108). TCT is typically delivered in 1 h sessions 3–5 h a week for ~20–40 h. At the group level patients with SZ show reduction in cognitive deficits which are linked to improved functional outcomes. However, 20–40% of subjects with SZ fail to show benefit, even in some cases, after 100 h of training (108–111). A biomarker measure that would identify which patients could benefit (or, conversely, which patients have a high likelihood of not benefitting) would be critical in scaling such a pro-cognitive intervention as part of a comprehensive neurorehabilitation strategy (112). As with malleability of MMN following initial exposure to memantine, MMN also appears to be a sensitive index of the neural systems engaged by the first “dose” of TCT exercises. In this context, Perez et al. found that MMN was a sensitive index of the perceptual learning that takes place in the first hour of training, with amplitude of MMN correlating with gains in auditory perceptual learning (113). More work has better elaborated this relationship, finding that on an individual level MMN changes in the direction of normalization after 1 h of TCT predict benefit from TCT after a full course (114).
Umbrellas and baskets in psychiatry: a possible future for clinical trials in psychiatry
With what is currently known about MMN and neurocognitive impairment in SZ, we can consider how EEG biomarkers can be used in the service of a precision medicine approach to clinical trials in psychiatry.
While pro-cognitive interventions for psychotic illnesses tend to focus on single diseases like SZ, cognitive impairment has been noted in related illnesses, including schizoaffective disorder and bipolar disorder with psychotic features. This parallels genetic evidence which supports a link between SZ, schizoaffective disorder and bipolar disorder. Despite this link, in traditional drug development pro-cognitive interventions are generally assessed in one population first (i.e., SZ), and then subsequent trials assess if such an intervention is useful in other related conditions. However, a basket-style precision medicine approach using EEG biomarkers could offer a more streamlined way to discover drugs targeted at transdiagnostically-related illness domains like cognitive impairment. For example, as shown in Figure 2A, a novel pro-cognitive trial testing a new Drug X could recruit patients with SZ, schizoaffective disorder and bipolar disorder and include only those who have MMN malleability. Since MMN malleability is a strong indicator of target engagement and neural plasticity, such an approach would enrich the study population to benefit from a pro-cognitive intervention. Furthermore, such a trial would test the effectiveness of a new intervention and would not necessarily be limited by traditional criteria, and have relevance across multiple illnesses (115).
Figure 2
Using EEG biomarkers to design basket and umbrella trials. (A) Using EEG-guided basket trials could allow for different psychiatric populations who share the same disease dimension to be given a therapeutic intervention, allowing more patients to potentially benefit. In this scheme subjects are separated by different colors to denote different diseases. Those who have favorable EEG biomarker profiles are indicated by solid coloring while those are not responsive are in outline. EEG-guided basket trials have the potential to select subjects for clinical trials assessing novel drugs for optimal response. (B) Similarly, using EEG-guided umbrella trials could allow for patients with the same illness to be assigned to different treatments, allowing for a more specific intervention strategy. In this scheme, subjects with different biological mechanisms underlying a particular illness domain are indicated by different gradations in coloring. EEG biomarkers can be used to assess which patients may be suitable for which intervention. EEG-guided umbrella trials have the potential to improve pragmatic clinical trials assessing treatment effectiveness.
Similarly, using EEG-guided umbrella designs in psychiatry would better improve pragmatic trials matching interventions to patient strengths. For example, in a SZ trial comparing different pro-cognitive interventions, positive response to particular EEG biomarkers would help stratify different treatment strategies (see Figure 2B). In such a trial, SZ patients with favorable auditory MMN malleability could receive TCT aimed to improve auditory sensory processing, while those with equivocal or poor MMN malleability could respectively receive pro-cognitive medications or specialized behavioral therapy.
These new trial designs are not without limitations. First, due to their relative novelty such designs have not yet been attempted in psychiatry, and thus there is little precedent for how these trials would be staged. Such trials require greater logistical burdens, require larger cohorts of patients, and are costlier to run. Furthermore, such trials may face barriers in recruiting enough patients with specific biomarker profiles, and experience challenges in balancing treatment arms. Both basket and umbrella trials would require new collaborative frameworks, and require nuanced statistical and administrative support.
Despite these potential limitations, using biomarkers to inform clinical trials in psychiatry holds the potential to improve our current understanding of psychiatric illness, and creates an additional way to determine the effectiveness of novel therapeutic strategies. Just as how various cancers are currently molecularly phenotyped, neurophysiologically-guided basket and umbrella trials could help “EEG-phenotype” cognitive impairment in illnesses like SZ. This precision-medicine approach would enhance the development of not only novel drugs, but also other comprehensive rehabilitation strategies in SZ like TCT.
While this mini-review has focused on neurophysiological biomarkers in SZ, the rationale described could broadly apply to other psychiatric illnesses and other types of biomarkers, including genetic and imaging biomarkers. We anticipate that as the tools of neuroscience allow us to understand complex diseases in a more nuanced way, further development of biomarker-informed precision medicine approaches to clinical trials will help further optimize matching the right treatment to the right patient.
Statements
Author contributions
Both authors have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by grants by the Sidney R. Baer, Jr. Foundation, Brain and Behavior Research Foundation, and Department of Veteran Affairs VISN-22 Mental Illness Research, Education, and Clinical Center (MIRECC).
Acknowledgments
The authors thank Rebecca Eliscu for assistance in creating Figure 2.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CA and handling editor declared their shared affiliation at the time of the review.
References
1.
InselTR. The NIMH experimental medicine initiative. World Psychiatry (2015) 14:151–3. 10.1002/wps.20227
2.
FriedmanAALetaiAFisherDEFlahertyKT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer (2015) 15:747–56. 10.1038/nrc4015
3.
KramerFSabbahHNJanuzziJJZannadFPeter van TintelenJSchelbertEBet al. Redefining the role of biomarkers in heart failure trials: expert consensus document. Hear Fail Rev. (2017) 22:263–77. 10.1007/s10741-017-9608-5
4.
RitterACummingsJ. Fluid biomarkers in clinical trials in Alzheimer's disease therapeutics. Front Neurol. (2015) 31:186. 10.3389/fneur.2015.00186
5.
MenisJHasanBBesseB. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev. (2015) 23:367–78. 10.1183/09059180.00004214
6.
SimonR. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther. (2017) 102:934–41. 10.1002/cpt.814
7.
TaoJJSchramAMHymanDM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. (2018) 69:319–31. 10.1146/annurev-med-062016-050343
8.
CoyneGOTakebeNChenAP. Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer (2017) 41:182–93. 10.1016/j.currproblcancer.2017.02.001
9.
BoraEBinnurAkdede BAlptekinK. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. (2017) 47:2401–13. 10.1017/S0033291717000952
10.
FioravantiMBianchiVCintiME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry (2012) 12:64. 10.1186/1471-244X-12-64
11.
SitskoornMMAlemanAEbischSJAppelsMCKahnRS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res. (2004) 71:285–95. 10.1016/j.schres.2004.03.007
12.
HeinrichsRWZakzanisKK. Neurocognitive deficits in schizophrenia: a quantitative review of the evidence. Neuropsychology (1998) 12:426–45. 10.1037/0894-4105.12.3.426
13.
GreenMFKernRSBraffDLMintzJ. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull. (2000) 26:119–36. 10.1093/oxfordjournals.schbul.a033430
14.
ZipurskyRB. Why are the outcomes in patients with schizophrenia so poor?J Clin Psychiatry (2014) 74:20–4. 10.4088/JCP.13065su1.05
15.
MatzaLSBuchananRPurdonSBrewster-JordanJZhaoYRevickiDA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull. (2006) 32:666–78. 10.1093/schbul/sbl004
16.
ThomasMLGreenMFHellemannGSugarCATarasenkoMCalkinsMEet al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiatry (2017) 74:37–46. 10.1001/jamapsychiatry.2016.2980
17.
BrownDNkagomeKCordesJBrennerRGrunderGKeefeRSEet al. Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial. Schizophr Bull. (2018). 10.1093/schbul/sby049. [Epub ahead of print].
18.
TalposJC. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia. Drug Discov Today (2017) 22:1017–26. 10.1016/j.drudis.2017.04.014
19.
GirgisRRZoghbiAWJavittDCLiebermanJA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. (2018). 10.1016/j.jpsychires.2018.07.006 [Epub ahead of print].
20.
GreenMFNueichterleinKHGoldJMBarchDMCohenJEssockSet al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 56:301–7. 10.1016/j.biopsych.2004.06.023
21.
GreenMFButlerPDChenYGeyerMASilversteinSWynnJKet al. Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull. (2009) 35:163–81. 10.1093/schbul/sbn156
22.
CarterCSBarchDMBuchananRWBullmoreEKrystalJHCohenJet al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 64:4–10. 10.1016/j.biopsych.2008.03.020
23.
ButlerPDChenYFordJMGeyerMASilversteinSMGreenMF. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull. (2012) 38:81–91. 10.1093/schbul/sbr106
24.
LightGANaatanenR. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proc Natl Acad Sci USA. (2013) 110:15175–6. 10.1073/pnas.1313287110
25.
NäätänenRGiallardAWMantysaloS. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol. (1978) 42:313–29. 10.1016/0001-6918(78)90006-9
26.
NäätänenRTedermWAlhoKLavikainenJ. Auditory attention and selective input modulation: a topographical ERP study. Neuroreport (1992) 3:493–6. 10.1097/00001756-199206000-00009
27.
NäätänenR. Attention and Brain Function. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc (1992).
28.
NäätänenR. The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear. (1995) 16:6–18. 10.1097/00003446-199502000-00002
29.
LightGASwerdlowNRRisslingAJRadantASugarCASprockJet al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcomes studies of schizophrenia. PLoS ONE (2012) 7:e39434. 10.1371/journal.pone.0039434
30.
NagaiTTadaMKiriharaKArakiTJindeSKasaiK. Mismatch negativity as a “translatable” brain marker toward early intervention for psychosis: a review. Front Psychiatry (2013) 4:115. 10.3389/fpsyt.2013.00115
31.
RisslingAJParkSHYoungJWRisslingMBSugarCASprockJet al. Demand and modality of directed attention modulate “pre-attentive” sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. (2013) 146:326–35. 10.1016/j.schres.2013.01.035
32.
ToddJMichiePTSchallUWardPBCattsSV. Mismatch negativity (MMN) reduction in schizophrenia—impaired prediction-error generation, estimation or salience?Int J Psychophysiol. (2012) 83:222–31. 10.1016/j.ijpsycho.2011.10.003
33.
NäätänenRPaavilainenPRinneTAlhoK. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol. (2007): 118:2544–90. 10.1016/j.clinph.2007.04.026
34.
AlhoK. Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNm) elicited by sound changes. Ear Hear. (1995) 16:38–51. 10.1097/00003446-199502000-00004
35.
TakahashiHRisslingAJPascual-MarquiRKiriharaKPelaMSprockJet al. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection response. Neuroimage (2013) 66:594–603. 10.1016/j.neuroimage.2012.09.074
36.
RisslingAJMiyakoshiMSugarCABraffDLMakeigSLightGA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. NeuroImage Clin. (2014) 6:424–37. 10.1016/j.nicl.2014.09.006
37.
ShelleyAMWardPBCattsSVMichiePTAndrewsSMcConaghyN. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry (1991) 30:1059–62. 10.1016/0006-3223(91)90126-7
38.
UmbrichtDKrljesS. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. (2005) 76:1–23. 10.1016/j.schres.2004.12.002
39.
JavittDCSteinschneiderMSchroederCEVaughanHGJrArezzoJC. Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res. (1994): 667:192–200. 10.1016/0006-8993(94)91496-6
40.
CattsSVShelleyAMWardPBLiebertBMcConaghyNAndrewsSet al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry (1995) 152:213–9. 10.1176/ajp.152.2.213
41.
JavittDCShelleyAMSilipoGLiebermanJA. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry (2000) 57: 1131–7. 10.1001/archpsyc.57.12.1131
42.
MichiePT. What has MMN revealed about the auditory system in schizophrenia?Int J Psychophysiol. (2001) 42:177–94. 10.1016/S0167-8760(01)00166-0
43.
UmbrichtDKollerRSchmidLSkraboAGrubelCHuberTet al. How specific are deficits in mismatch negativity generation to schizophrenia?Biol Psychiatry (2003) 53:1120–31. 10.1016/S0006-3223(02)01642-6
44.
SalisburyDFKurokiNKasaiKShentonMEMcCarleyRW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry (2007) 64:521–9. 10.1001/archpsyc.64.5.521
45.
SalisburyDFShentonMEGriggsCBBonner-JacksonAMcCarleyRW. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry (2002) 59:686–94. 10.1001/archpsyc.59.8.686
46.
LightGASwerdlowNRThomasMLCalkinsMEGreenMFGreenwoodTAet al. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. (2015) 163:63–72. 10.1016/j.schres.2014.09.042
47.
Brockhaus-DumkeATendolkarIPukropRSchultze-LutterFKlosterkötterJRuhrmannS. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr Res. (2005) 73:297–310. 10.1016/j.schres.2004.05.016
48.
OkninaLBWild-WallNOadesRDJuranSARopckeBPfuellerUet al. Frontal and temporal sources of mismatch negativity in healthy controls, patients at onset of schizophrenia in adolescence and others at 15 years after onset. Schizophr Res. (2005) 76:25–41. 10.1016/j.schres.2004.10.003
49.
OadesRDWild-WallNJuranSASachsseJOkninaLBRöpckeB. Auditory change detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in patients with a first episode in adolescence, and patients 14 years after an adolescent illness-onset. BMC Psychiatry (2006) 6:7. 10.1186/1471-244X-6-7
50.
JoshiYBBreitensteinBTarasenkoMThomasMLChangWLSprockJet al. Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia. Schizophr Res. (2018) 191:5–9. 10.1016/j.schres.2017.05.020
51.
BodatschMRuhrmannSWagnerMMüllerRSchultze-LutterFFrommannIet al. Prediction of psychosis by mismatch negativity. Biol Psychiatry (2011) 69:959–66. 10.1016/j.biopsych.2010.09.057
52.
KirinoEInoueR. The relationship of mismatch negativity to quantitative EEG and morphological findings in schizophrenia. J Psych Res. (1999) 33:445–56. 10.1016/S0022-3956(99)00012-6
53.
FawzyNGadoOAbdallaAMIbrahimWM. Auditory mismatch negativity, P300, and disability among first-episode schizophrenia patients without auditory hallucinations. Egypt J Psychiatry (2015) 36:112. 10.4103/1110-1105.158120
54.
DüringSGlenthøjBYOranjeB. Effects of blocking D2/D3 receptors on mismatch negativity and P3a amplitude of initially antipsychotic naïve, first episode schizophrenia patients. Int J Neuropsychopharmacol. (2016) 19:pyv109. 10.1093/ijnp/pyv109
55.
UmbrichtDJavittDNovakGBatesJPollackSLiebermanJet al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry (1998) 44:716–25. 10.1016/S0006-3223(97)00524-6
56.
UmbrichtDJavittDNovakGBatesJPollackSLiebermanJet al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. (1999) 2:299–304. 10.1017/S1461145799001595
57.
SchallUCattsSVKarayanidisFWardPB. Auditory event-related potential indices of fronto-temporal information processing in schizophrenia syndromes: valid outcome prediction of clozapine therapy in a three-year follow-up. Int J Neuropsychopharmacol. (1999) 2:83–93. 10.1017/S1461145799001418
58.
RisslingAJBraffDLSwerdlowNRHellemannGRassovskyYSprockJet al. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. (2012) 123:1942–9. 10.1016/j.clinph.2012.02.079
59.
JahshanCCadenheadKSRisslingAJKiriharaKBraffDLLightGA. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med. (2012) 42:85–97. 10.1017/S0033291711001061
60.
AtkinsonRJMichiePTSchallU. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry (2012) 71:98–104. 10.1016/j.biopsych.2011.08.023
61.
ShaikhMValmaggiaLBroomeMRDuttALappinJDayFet al. Reduced mismatch negativity predates the onset of psychosis. Schizophr Res. (2012) 134:42–8. 10.1016/j.schres.2011.09.022
62.
HiguchiYSumiyoshiTSeoTMiyanishiTKawasakiYSuzukiM. Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PLoS ONE (2013) 8:e54080. 10.1371/journal.pone.0054080
63.
PerezVBWoodsSWRoachBJFordJMMcGlashanTHSrihariVHet al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry (2014) 75:459–69. 10.1016/j.biopsych.2013.07.038
64.
KoshiyamaDKiriharaKTadaMNagaiTFujiokaMKoikeSet al. Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis. Schizophr Res. (2018) 195:378–84. 10.1016/j.schres.2017.09.045
65.
Fusar-PoliPBonoldiIYungARBorgwardtSKemptonMJValmaggiaLet al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry (2012) 69:220–9. 10.1001/archgenpsychiatry.2011.1472
66.
CannonTDCadenheadKCornblattBWoodsSWAddingtonJWalkerEet al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 65:28–37. 10.1001/archgenpsychiatry.2007.3
67.
CattsVSLaiYLWeickertCSWeickertTWCattsSV. A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: how can we link molecular abnormalities to mismatch negativity deficits?Biol Psychol. (2016) 116:57–67. 10.1016/j.biopsycho.2015.10.013
68.
MichiePTMalmiercaMSHarmsLToddJ. The neurobiology of MMN and implications for schizophrenia. Biol Psychol. (2016):116:90–97. 10.1016/j.biopsycho.2016.01.011
69.
JavittDCZukinSRHeresco-LevyUUmbrichtD. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. (2012) 38:958–66. 10.1093/schbul/sbs069
70.
RosburgTKreitschmann-AndermahrI. The effects of ketamine on the mismatch negativity (MMN) in humans–a meta-analysis. Clin Neurophysiol. (2016) 127:1387–94. 10.1016/j.clinph.2015.10.062
71.
Gil-da-CostaRStonerGRFungRAlbrightTD. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc Natl Acad Sci USA. (2013) 110:15425–30. 10.1073/pnas.1312264110
72.
UmbrichtDKollerRVollenweiderFXSchmidL. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry (2002) 51:400–6. 10.1016/S0006-3223(01)01242-2
73.
Kreitschmann-AndermahrIRosburgTDemmeUGaserENowakHSauerH. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res. (2001) 12:109–16. 10.1016/S0926-6410(01)00043-X
74.
NagaiTKiriharaKTadaMKoshiyamaDKoikeSSugaMet al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis. Sci Rep. (2017) 7:2258. 10.1038/s41598-017-02267-1
75.
RowlandLMSummerfeltAWijtenburgSADuXChiappelliJJKrishnaNet al. Frontal glutamate and gamma-aminobutyric acid level and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry (2016) 73:466–74. 10.1001/jamapsychiatry.2015.2680
76.
HallMHSchulzeKRijsdijkFPicchioniMEttingerUBramonEet al. Heritability and reliability of p300, P50 and duration mismatch negativity. Behav Genet. (2006) 36:845–57. 10.1007/s10519-006-9091-6
77.
HongLEMoranLVDuXO'DonnellPSummerfeltA. Mismatch negativity and low frequency oscillations in schizophrenia families. Clin Neurophysiol. (2012) 123:1980–8. 10.1016/j.clinph.2012.03.011
78.
EarlsHACurranTMittalV. A meta-analytic review of auditory event-related potential components as endophenotypes for schizophrenia: perspectives from first-degree relatives. Schizophr Bull. (2016) 42:1504–16. 10.1093/schbul/sbw047
79.
EricksonMARuffleAGoldJM. A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. Biol Psychiatry (2016) 79:980–7. 10.1016/j.biopsych.2015.08.025
80.
RanlundSAdamsRADiezAConstanteMDuttAHallMHet al. Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity. Hum Brain Mapp. (2016) 37:351–65. 10.1002/hbm.23035
81.
ZarchiOCarmelMAvniCAttiasJFrischAMichaelovskyEet al. Schizophrenia-like neurophysiological abnormalities in 22q11.2 deletion syndrome and their association to COMT and PRODH genotypes. J Psychiatr Res. (2013) 47:1623–9. 10.1016/j.jpsychires.2013.07.004
82.
LightGABraffDL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry (2003) 162:1741–3. 10.1176/appi.ajp.162.9.1741
83.
WynnJKSugarCHoranWPKernRGreenMF. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol Psychiatry (2010) 67:940–7. 10.1016/j.biopsych.2009.11.024
84.
RasserPESchallUToddJMichiePTWardPBJohnstonPet al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr Bull. (2011) 37:131–40. 10.1093/schbul/sbp060
85.
KawakuboYKasaiK. Support for an association between mismatch negativity and social functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1367–8. 10.1016/j.pnpbp.2006.03.003
86.
LeeSHSungKLeeKSMoonEKimCG. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2014) 48:213–9. 10.1016/j.pnpbp.2013.10.010
87.
KishiTIkutaTOyaKMatsunagaSMatsudaYIwataN. Anti-dementia drugs for psychophathology and cognitive impairment in schizophrenia: a systematic review and meta-analysis. Int J Neuropsychopharmacol. (2018) 21:748–57. 10.1093/ijnp/pyy045
88.
DiIorioBaroniGLorussoMMontemitroCSpanoMCdi GiannanotonioM. Efficacy of memantine in schizophrenia patients: a systematic review. J Amino Acids (2017) 2017:7021071. 10.1155/2017/7021071
89.
ZdanysKTampiRR. A systematic review of off-label uses of memantine for psychaitric disorder. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32:1362–74. 10.1016/j.pnpbp.2008.01.008
90.
JohnsonJWKotermanskiSE. Mechanism of action of memantine. Curr Opin Pharmacol. (2006) 6:61–7. 10.1016/j.coph.2005.09.007
91.
LiptonSA. The molecular basis of memantine action in Alzheimer's disease and other neurological disorder: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. (2005) 2:155–65. 10.2174/1567205053585846
92.
SwerdlowNRvan BergeijkDPBergsmaFWeberETalledoJ. The effects of memantine on prepulse inhibition. Neuropsychopharmacology (2009). 34:1854–64. 10.1038/npp.2009.7
93.
KishiTMatsudaYIwataN. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (2017) 234:2113–25. 10.1007/s00213-017-4616-7
94.
ZhengWLiXHYangXHCaiDBUngvariGSNgCHet al. Adjunctive use of memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. (2018) 48:72–81. 10.1017/S0033291717001271
95.
SwerdlowNRBhaktaSChouHHTelledoJABalvanedaBLightGA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacology (2016) 41:419–30. 10.1038/npp.2015.162
96.
BhaktaSGChouHHRanaBTelledoJABalvanedaBGaddisLet al. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: testing an experimental medicine strategy. Psychopharmacology (2016) 233:2399–410. 10.1007/s00213-016-4291-0
97.
KirbyJGreenCLovemanECleggAPicotJTakedaAet al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging (2006) 23:227–40. 10.2165/00002512-200623030-00005
98.
AreosaSASherriffFMcShaneR. Memantine for dementia. Cochrane Database Syst Rev. (2005) CD003154.
99.
VeermanSRSchultePFSmithJDde HaanL. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind placebo-controlled crossover study. Psychol Med. (2017) 46:1909–21. 10.1017/S0033291716000398
100.
VeermanSRSchultePFDeijenJBde HaanL. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med. (2017) 47:363–75. 10.1017/S0033291716002476
101.
MazinaniRNejatiSKhodaeiM. Effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized dobule-blind placebo-controlled clinical trial. Psychiatry Res. (2017) 247:291–5. 10.1016/j.psychres.2016.09.028
102.
IvlevaEIClementzBADutcherAMArnoldSJMJeon-SlaughterHAslanSet al. Brain structure biomarkers in the psychosis biotypes: findings from the bipolar-schizophrenia network for intermediate phenotypes. Biol Psychiatry (2017) 82:26–39. 10.1016/j.biopsych.2016.08.030
103.
SwerdlowNRBhaktaSGLightGA. Room to move: plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. Schizophr Res. (2018) 199:285–91. 10.1016/j.schres.2018.03.037
104.
LightGAZhangWJoshiYBBhaktaSTalledoJASwerdlowNR. Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia. Neuropsychopharmacology (2017) 42:2633–9. 10.1038/npp.2017.81
105.
KantrowitzJTSwerdlowNRDunnWVinogradovS. Auditory system target engagement during plasticity-based interventions in schizophrenia: a focus on modulation of N-methyl-D-aspartate-type glutamate receptor function. Biol Psychiatry Cogn Neurosci Neuroimaging (2018) 3:581–90. 10.1016/j.bpsc.2018.02.002
106.
FisherMHarmanAStephensDBVinogradovS. Neuroscience-informed computer-assisted cognitive training in schizophrenia. Ann NY Acad Sci. (2016) 1366:90–114. 10.1111/nyas.13042
107.
GenevskyAGarrettCTAlexanderPPVinogradovS. Cognitive training in schizophrenia: a neuroscience-based approach. Dialogues Clin Neurosci. (2010) 12:416–21.
108.
LoewyRFisherMSchlosserDABiagiantiBStuartBMathalonDHet al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schiophr Bull. (2016) 42 (Suppl. 1):S118–26. 10.1093/schbul/sbw009
109.
FisherMMellonSHWolkowitzOVinogradovS. Neuroscience-informed auditory training in schizophrenia: a final report of the effects on cognition and serum brain-derived neurotrophic factor. Schizophr Res Cogn. (2016) 3:1–7. 10.1016/j.scog.2015.10.006
110.
DaleCLBrownEGFisherMHermanABDowlingAFHinkleyLBet al. Auditory cortical plasticity drives training-induced cognitive changes in schizophrenia. Schizophr Bull. (2016) 42:220–8. 10.1093/schbul/sbv087
111.
FisherMLoewyRCarterCLeeARaglandJDNiendamTet al. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull. (2015) 41:250–8. 10.1093/schbul/sbt232
112.
VinogradovSFisherMNagarajanS. Cognitive training in schizophrenia: golden age or wild west?Biol Psychiatry (2013) 73:935–7. 10.1016/j.biopsych.2013.03.015
113.
PerezVBTarasenkoMMiyakoshiMPiankaSTMakeigSDBraffDLet al. Mismatch negativity is a sensitive and predictive biomarker of perceptual learning during auditory cognitive training in schizophrenia. Neuropsychopharmacology (2017) 42:2206–13. 10.1038/npp.2017.25
114.
HochbergerWCJoshiYBThomasMLZhangWBismarkAWTreichlerEBHet al. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology (in press).
115.
BraffDLLightGA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (2004) 174:75–85. 10.1007/s00213-004-1848-0
Summary
Keywords
schizophrenia, mismatch negativity, biomarker, clinical trial, cognitive impairment
Citation
Joshi YB and Light GA (2018) Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia. Front. Psychiatry 9:554. doi: 10.3389/fpsyt.2018.00554
Received
30 July 2018
Accepted
15 October 2018
Published
19 November 2018
Volume
9 - 2018
Edited by
Stefan Borgwardt, Universität Basel, Switzerland
Reviewed by
Amineh Koravand, University of Ottawa, Canada; Christina Andreou, Universitäre Psychiatrische Kliniken Basel, Switzerland
Updates
Copyright
© 2018 Joshi and Light.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gregory A. Light glight@ucsd.edu
This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.